Associate Professor of Dermatology, Massachusetts General Hospital

Dermatology

Dr. Hensin Tsao is an expert in the field of Dermatology. He went to medical school at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical college. Columbia University College of Physicians & Surgeons is ranked 8/52 in Research/PrimaryCare. He received 6 awards: "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Elected Member", "Super Doctor" and "Fellow (FAAD)". Hensin Tsao, MD is a published MD. He published 33 publications, including: 'Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling.' He accepts Medicare payments and is listed with Medicare.gov.

Publications

---

• Hereditary Melanoma: Update on syndromes and management: Emerging Melanoma cancer complexes and genetic counseling.
• Hereditary Melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole Melanoma syndrome.
• Gender Disparity and Mutation Burden in Metastatic Melanoma.
• Genetics of melanocytic nevi.
• Concerns About Presence of a Wild-Type BAP1 Allele in Absence of Nuclear Protein Expression-Reply.
• Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.
• Early detection of Melanoma: Reviewing the ABCDEs.
• MITF Modulates Therapeutic Resistance through EGFR Signaling.
• Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype.
• Outcome of patients with de novo versus nevus-associated Melanoma.
• EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma.
• BAP1 Plays a Survival Role in Cutaneous Melanoma.
• Epidermal, Sebaceous, and Melanocytic Nevoid Proliferations Are Spectrums of Mosaic RASopathies.
• The utility of re-excising mildly and moderately dysplastic nevi: A retrospective analysis.
• Molecular testing in Melanoma.
• Melanocytes Are Selectively Vulnerable to UVA-Mediated Bystander Oxidative Signaling.
• Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses Melanoma viability and tumor growth.
• CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF mutant Melanoma.
• The Skin microbiome: Current perspectives and future challenges.
• Update on the Epidemiology of Melanoma.
• Melanoma genetics: the other side.
• The distribution of microscopic Melanoma metastases in sentinel lymph nodes: implications for pathology protocols.
• Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma.
• Melanoma: from mutations to medicine.
• Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families.
• Histologically challenging melanocytic tumors referred to a tertiary care pigmented Lesion clinic.
• X-chromosome inactivation and Skin disease.
• Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside.
• Small RNAs in development and disease.
• Melanoma: Clinical Features and Genomic Insights.
• Melanoma susceptibility genes and risk assessment.
• Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival.

Schools

---

• Columbia University College Of Physicians and Surgeons

• Brigham and Womens39 Hospital

• Harvard Med School

• Mass General Hospital

Procedures Preformed

---

• Destruction of Benign Skin Lesion
• Excision of Benign Skin Lesion
• Excision of Malignant Skin Lesion
• Shaving of Skin Lesion

Conditions Treated

---

• Actinic Keratosis
• Basal Cell Carcinoma
• Benign Skin Lesion
• Carcinoma in Situ of Skin
• View All

Doctors Specialties

---

• Dermatology

Accepted Insurances

---

Awards

---

• America's Top Doctors
• Boston Magazine
• America's Top Doctors for Cancer
• Elected Member
• Super Doctor
• Fellow (FAAD)

Education

---

• Massachusetts General Hospital
• Brigham and Women's Hospital
• Columbia University College of Physicians & Surgeons

Hospital

---

• Massachusetts General Hospital

Drug Facts

---

NPI NUMBER		1295719292
NPPES Provider LastName		TSAO
NPPES Provider FirstName		HENSIN
NPPES Provider ZIPCode		021142517
NPPES Provider State		MA
Specialty Description		Dermatology
Total Claim Count		23.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1295719292
Last Name Of The Provider	TSAO
First Name Of The Provider	HENSIN
View All

Similar Doctors

---

	Dr. Thomas S. Kupper, MD This Doctor is OpenDoctor Recommended.
	Dr. Deirdre F. Murrell, MD
	Dr. Catherine S. Yang, MD
	Dr. Maria Beatrice A. Palli, MD This Doctor is OpenDoctor Recommended.
	Dr. Roberto R. Ricardo-Gonzalez, MD
	Dr. Alina Markova, MD This Doctor is OpenDoctor Recommended.
	Dr. Joannes M. Grevelink, MD This Doctor is OpenDoctor Recommended.
	Dr. Sheilagh M. Maguiness, MD This Doctor is OpenDoctor Recommended.
	Dr. Jessica L. Fewkes, MD This Doctor is OpenDoctor Recommended.
	Dr. Ellen K. Roh, MD This Doctor is OpenDoctor Recommended.
	Dr. Jag Bhawan, MD This Doctor is OpenDoctor Recommended.
	Dr. Martina Porter, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog